PI3K inhibitor X

CAS No. 956958-53-5

PI3K inhibitor X( XL-147 analog )

Catalog No. M16833 CAS No. 956958-53-5

PI3K inhibitor X (XL-147 analog) is a derivative of XL147 that acts as a reversible inhibitor.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 29 Get Quote
5MG 45 Get Quote
10MG 72 Get Quote
25MG 128 Get Quote
50MG 205 Get Quote
100MG 354 Get Quote
200MG 460 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    PI3K inhibitor X
  • Note
    Research use only, not for human use.
  • Brief Description
    PI3K inhibitor X (XL-147 analog) is a derivative of XL147 that acts as a reversible inhibitor.
  • Description
    PI3K inhibitor X (XL-147 analog) is a derivative of XL147 that acts as a reversible inhibitor of class I PI3Ks with IC50 of 39, 36, 23 and 383 nM for p110α, δ, γ and β respectively; Compound 147 in patent WO2012006552A1.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    XL-147 analog
  • Pathway
    PI3K/Akt/mTOR signaling
  • Target
    PI3K
  • Recptor
    DNA-PK|PI3Kα|PI3Kβ|PI3Kγ|PI3Kδ
  • Research Area
    Cancer
  • Indication
    ——

Chemical Information

  • CAS Number
    956958-53-5
  • Formula Weight
    448.5208
  • Molecular Formula
    C21H16N6O2S2
  • Purity
    >98% (HPLC)
  • Solubility
    10 mM in DMSO
  • SMILES
    O=S(C1=CC=C(C)C=C1)(NC2=NC3=CC=CC=C3N=C2NC4=CC5=NSN=C5C=C4)=O
  • Chemical Name
    Benzenesulfonamide, N-[3-(2,1,3-benzothiadiazol-5-ylamino)-2-quinoxalinyl]-4-methyl-

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Carlos L. Arteaga, et al. Combinations of kinase inhibitors for the treatment of cancer. WO 2012006552 A1.
molnova catalog
related products
  • 3-Methyladenine

    A selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 uM and 60 uM in HeLa cells.

  • B591

    B591 (B-591) is a potent, specific pan-PI3K inhibitor with IC50 of 1.3/0.36/1.1/1.58 uM for PI3Kα/β/γ/δ, respectively.

  • RLY-2608

    RLY-2608 is a selective mutant PI3Kα inhibitor that inhibits tumor growth in a PIK3CA mutant xenograft model.